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Dissolution profi les of perindopril and indapamide in their 
fi xed-dose formulations by a new HPLC method and diﬀ erent 
mathematical approaches
A new HPLC method was introduced and validated for si-
multaneous determination of perindopril and indapamide. 
Validation procedure included specifi city, sensitivity, ro-
bustness, stability, linearity, precision and accuracy. The 
method was used for the dissolution test of perindopril and 
indapamide in three fi xed-dose formulations. The dissolu-
tion procedure was optimized using diﬀ erent media, dif-
ferent pH of the buﬀ er, surfactants, paddle speed and tem-
perature. Similarity of dissolution profi les was estimated 
using diﬀ erent model-independent and model-dependent 
methods and, additionally, by principal component analy-
sis (PCA). Also, some kinetic models were checked for dis-
solved amounts of drugs as a function of time. 
Keywords: perindopril, indapamide, dissolution profi les, 
model-independent methods, model-dependent methods, 
PCA
One example in the area of anti-hypertensive polytherapy is the use of an angiotensin 
converting enzyme inhibitor, e.g., perindopril, and a diuretic, e.g., indapamide (Fig. 1) in 
one fi xed-dose formulation (1).
Bearing in mind previous reports concerning simultaneous determination of perin-
dopril and indapamide, some spectrophotometric methods were developed (2–5). Also, a 
few HPLC methods were elaborated and validated in the range of oﬃ  cial requirements 
(5–9). However, none of the above methods was applied to the dissolution study of perin-
dopril and indapamide in their fi xed-dose combinations.
A dissolution test is necessary to control the product properties within a batch and 
between batches. It is also needed in bioequivalence studies where similarity of dissolu-
tion profi les between a test product and a reference product should be demonstrated (10). 
A wide range of methods are available for comparison of dissolution profi le data 
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agreement about the best method. Some suggestions from the literature point to the neces-
sity of stricter criteria on the diﬀ erence allowed between two dissolution profi les (11, 17). 
Therefore, the question of the size of diﬀ erence between the test and reference profi les 
should be allowed has a practical as well as scientifi c signifi cance. Successful resolution of 
this issue may lead to the development of more appropriate methods for the comparison 
of dissolution profi le data. 
Thus, the fi rst goal of the present study was to elaborate a new reliable HPLC method 
and a new optimized dissolution test for the simultaneous determination of perindopril 
and indapamide. The second goal was to compare the dissolution profi les of three fi xed-




Perindopril arginine (Oril Industrie, France) was obtained as a gift  from Anpharm (Po-
land). Perindopril erbumine (tert-butyl amine) and indapamide were purchased from Sigma- 
-Aldrich Chemicals (USA). Three fi xed-dose formulations, i.e. Noliprel Forte® (NF) contain-
ing 5.0 mg of perindopril arginine and 1.25 mg of indapamide from Anpharm and Tertensif 
Kombi® (TK) (Servier, France), and Co-Prenessa® (CP) containing 4.0 mg of perindopril er-
bumine and 1.25 mg of indapamide from Krka (Poland) were used. The NF and TK tablets 
contained the same excipients, i.e. lactose monohydrate, magnesium stearate, maltodextrin, 
anhydrous colloidal silicon dioxide, sodium carboxymethyl starch type A, glycerol, hypro-
melose, Macrogol 6000 and titanium dioxide. Excipients for the CP tablets were microcrys-
talline cellulose, lactose monohydrate, sodium bicarbonate and colloidal silicon dioxide.
All solvents for chromatography, cetylpyridinium chloride (CPC) and Tween 80, were 
purchased from E. Merck (Germany). All other chemicals were supplied by Sigma-Aldrich 
Chemicals. Buﬀ ers of pH 2.6, 3.0 and 3.4 were prepared with 0.1 mol L–1 KH2PO4 and 85 % 
H3PO4. Buﬀ ers of pH 5.0, 5.5, 6.0 and 6.8 were prepared according to the European Pharma-
copoeia (18).
Equipment
The HPLC system from Waters (USA) consisted of an Alliance e2695 separation mod-

















Fig. 1. Chemical structures of: a) indapamide and b) perindopril.
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power Pro v.2.0 soft ware. Separation was carried out on a LiChrospher® 100 RP18 column 
(125 mm×4.0 mm i.d., with a particle size of 5 μm) from E. Merck. For the dissolution study, 
an Evolution 6100 bathless dissolution system from Distek Inc. (USA) was used (paddle 
apparatus). The pH measurements were performed with a model HI9024C pH-meter from 
Hanna Instruments (Italy).
Dissolution studies
Dissolution was performed using 500 mL of phosphate buﬀ er of pH 6.0 containing 
0.5 % Tween 80 at 100 rpm and 37 °C. For every individual assay, two respective tablets 
were used to gain a concentration over the linearity range. At the time intervals 10, 20, 30, 
40, 50 and 60 min, the samples were taken, fi ltered by nylon membrane fi lters (0.45 μm) and 
analyzed by the proposed HPLC method. 
Stability in dissolution medium
Samples of perindopril and indapamide in the dissolution medium were heated in a 
water bath at 37 °C under continuous stirring. Respective volumes were taken at time in-
tervals of 30, 60 and 90 min, diluted with the mobile phase to gain a concentration over the 
linearity range and analyzed by the proposed HPLC method for the presence of some ad-
ditional peaks or changes of the existing ones.
Calculations and soft ware
The obtained dissolutions profi les of perindopril and indapamide were compared by 
the model-independent methods, i.e. diﬀ erence and similarity factors f1 and f2, Rescigno 
indices ξ1 and ξ2, Mahalanobis distance (MD), the area under the dissolution curve (AUC) 
and the mean residence time of drug molecules in the dosage form (MRT). In addition, 
principal component analysis (PCA) was applied to visualize the diﬀ erences between 
three fi xed-dose formulations. 
Also, a number of kinetic models with dissolved amounts of drugs as a function of 
time were constructed and compared with the Akaike Information Criterion (AIC). The 
model-dependent methods, i.e., the maximum fraction of the drug released at infi nite time 
(Fmax), Weibull method and the release rate constant (k1) were used for further comparison. 
The Rescigno indices, AUC and MRT as well as AIC values were calculated based on the 
theoretical basis and equations proposed by Adams et al. (17) and Zhang et al. (19). All 
computations for the above parameters as well as PCA were performed using a free GNU 
R computational environment. The f1 and f2, MD as well as Weibull method were from 
Statistica® v. 10.0 containing Dissolution Profi les module (StatSoft , Poland). 
HPLC
The mobile phase containing acetonitrile, methanol and phosphate buﬀ er of pH 3.0 
(50:3:47, V/V/V) was used. It was fi ltered through the nylon membrane fi lter (0.45 μm) and 
degassed prior to use. Separation was carried out on a LiChrospher® 100 RP18 column with 
a fl ow rate of the mobile phase equal 0.7 mL min–1 while the temperature of the column 
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was 30 °C. The working solutions (20 μL volumes) were injected and monitored spectro-
photometrically at 210 nm. 
Solutions
Perindopril and indapamide stock solutions were prepared by dissolving 10 mg of 
pure compounds in methanol to obtain a concentration of 1 mg mL–1 and then by diluting 
with methanol 10 times. All working solutions were prepared by respective diluting the 
above solutions with the mobile phase. 
Validation
HPLC method was validated for specifi city, robustness, stability, linearity, precision 
and accuracy, according to ICH guidelines (20).
Stability in working solutions. – The working solutions at the concentration of 40 μg mL–1 
of perindopril and 10 μg mL–1 of indapamide were stored at temperature of 25 °C for 6, 12, 
24 and 48 h in tightly capped volumetric fl asks. The stability of drugs was then checked by 
analyzing chromatograms for the presence of some additional peaks or changes of the 
existing ones.
Robustness. – Robustness of HPLC method was checked aft er deliberate alterations of 
the buﬀ er in the mobile phase (in the range 2.9–3.1), the fl ow rate of the mobile phase (in 
the range 0.5–0.9 mL min–1) and the column temperature (in the range 21–23 °C), using one 
concentration of perindopril and indapamide over the linearity range (40 μg mL–1 of per-
indopril and 10 μg mL–1 of indapamide). Robustness of the dissolution was checked aft er 
small alterations of % Tween 80 in the medium (in the range 0.4–0.6 %), pH of the buﬀ er in 
the medium (in the range 5.9–6.1) and temperature (in the range 36–38 °C), using tablets 
from one two-component formulation (TK). The eﬀ ects of a single factor at three levels, 
nominal, lower and upper, were estimated in individual sets. Resolution factor (Rs) be-
tween perindopril and indapamide as well as recoveries of the drugs were then deter-
mined for robustness testing.
Calibration and limiting values. – Calibration solutions were prepared over the concen-
tration ranges 12–60 μg mL–1 for perindopril and 3–15 μg mL–1 for indapamide. Injection 
of 20 μL of each working solution was repeated six times for each sample. The peak areas 
were then plott ed against the corresponding drug concentrations. Limit of detection (LOD) 
and limit of quantifi cation (LOQ) were calculated from the equations of LOD = 3.3 × SD/a 
and LOQ = 10 × SD/a, using the SD of the intercept of the regression line in proximity of 
LOD and the slope of the calibration curve (a) (20).
Precision. – Precision of the method was evaluated by injecting the working solutions 
at three diﬀ erent concentrations (24, 40, 56 μg mL–1of perindopril and 6, 10, 14 μg mL–1 of 
indapamide). These solutions were analyzed three times within the same day (within-day 
precision) and three times over a period of three days (day-to-day precision).
Accuracy. – Accuracy was evaluated by the standard addition method at three levels. 
Weighed portions of powdered tablets containing 8 or 10 mg of perindopril and 2.5 mg of 
indapamide were transferred to 100-mL fl asks, sonicated for 15 min, diluted to the mark 
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and fi ltered through nylon membrane fi lters (0.45 μm). Then, 1.2-, 2.0- and 2.8-mL volumes 
of these extracts were fortifi ed with 2.0-mL volumes of the standard solutions of perindo-
pril and indapamide (0.1 mg mL–1), diluted to 10 mL and analyzed by HPLC method in the 
same day and three times over a period of three days. The assay was repeated three times 
at each level of addition. The results were estimated by calculating the respective recover-
ies of drugs.
Assay in tablets 
Weighed portions of powdered tablets containing 8 or 10 mg of perindopril and 2.5 
mg of indapamide were transferred to 100-mL fl asks, sonicated for 15 min, diluted to the 
mark and fi ltered through nylon membrane fi lters (0.45 μm). Then, 3.0-mL volumes were 
diluted to 10 mL and analyzed by HPLC. The assay was repeated six times, individually 
weighing the respective tablet powders. The results were estimated by checking if the 
determined concentrations of the compounds were inside respective 95 % confi dence in-
tervals as well as by calculating RSD values.
RESULTS AND DISCUSSION
Chromatography optimization
Mobile phases containing acetonitrile, methanol and diﬀ erent phosphate buﬀ ers (pH 
2.6, 3.0 and 3.4) were examined. Also, the eﬀ ects of the fl ow rate of the mobile phase (0.5–1.0 
mL min–1) and column temperature (25–40 °C) were checked. 
The mobile phase containing acetonitrile, methanol and phosphate buﬀ er of pH 3.0 
(50:3:47, V/V/V) with the fl ow rate of 0.7 mL min–1 was fi nally used at 30 °C. As a result, well 
defi ned and resolved peaks with mean retention times of ca. 2.9 and 4.6 min, for perindo-
pril and indapamide, respectively, were obtained (Fig. 2).
The chromatographic system was checked by repetitively injecting the drug solution 
at concentration level of 40 μg mL–1 for perindopril and 10 μg mL–1 for indapamide and 
then by estimating parameters such as peak symmetry, resolution factor and theoretical 
plate number. All results were satisfactory and indicated suﬃ  cient eﬀ ectiveness of the 
system for perindopril and indapamide assessment (Table I).
Validation
Specifi city. – Specifi city of the method was proven by the lack of interference peaks 
from excipients present in formulations as well as by the peak-purity function. Chromato-
grams obtained from two-component tablets were almost identical to those obtained from 
the standard solutions of perindopril and indapamide (Fig. 2).
Robustness. – Robustness of the method was checked aft er deliberate alterations of 
some operational parameters including pH of the buﬀ er in the mobile phase, the fl ow rate 
of the mobile phase and column temperature. It was shown that RSD from recoveries was 
0.7 % for perindopril and in the 0.4–0.5 % for indapamide. At the same time, the RSD for 
the Rs ranged from 1.3 to 1.5 %. All results are presented in Table II.
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Fig. 2. Representative chromatograms of indapamide (IND) and perindopril (PER) from: 
a) standard solution and b) from the marketed formulation. HPLC conditions are described 
in the text.
Stability. – The drugs resolved in methanol were stable when stored at 25 °C for 48 h 
and no additional peaks or changes of the existing ones were observed in the chromato-
grams. Further, the samples in the dissolution medium, heated at 37 °C for 90 min did not 
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show any signifi cant change. Recoveries of both drugs from stored solutions, in compari-
son with the respective standards, were ranged from 98.5 to 101.5 %.
Table I. Chromatographic parameters of the proposed method
Parameter Perindopril (n = 6) Indapamide (n = 6)
Retention time (min) 2.9 4.6
Peak width at h½ (min) 0.1 0.3
Peak width at the base (min) 0.3 0.6
Asymmetry factor 1.19 1.23
Resolution factor – 3.58
Theoretical plate number (N m–1) 37273 10418
Table II. Robustness of the HPLC method and the dissolution procedure









pH of the buﬀ er in the 
mobile phase
2.9 98.01 ± 0.71 101.0 ± 0.39 3.59 ± 0.04
3.0 98.45 ± 0.78 0.72 100.6 ± 0.45 0.37 3.58 ± 0.04 1.25
3.1 99.49 ± 0.67 100.8 ± 0.34 3.63 ± 0.05
Flow rate of the mobile 
phase (mL min–1)
0.5 99.35 ± 0.75 100.1 ± 0.41 3.67 ± 0.06
0.7 98.45 ± 0.65 0.73 100.6 ± 0.43 0.46 3.58 ± 0.05 1.47
0.9 100.0 ± 0.67 101.4 ± 0.58 3.54 ± 0.05
Column temperature 
(°C)
21 99.67 ± 0.73 100.8 ± 0.53 3.68 ± 0.06
22 98.45 ± 0.67 0.66 100.6 ± 0.59 0.54 3.58 ± 0.03 1.36
23 99.89 ± 0.58 99.78 ± 0.53 3.61 ± 0.05
pH of the buﬀ er in the 
dissolution medium
5.9 84.67 ± 0.45 85.23 ± 0.52 –
6.0 84.25 ± 0.53 0.61 85.05 ± 0.48 0.58 –
6.1 85.10 ± 0.58 85.34 ± 0.52 –
% Tween 80 in the 
dissolution medium
0.4 85.34 ± 0.43 84.98 ± 0.48 –
0.5 84.25 ± 0.56 0.56 85.05 ± 0.49 0.58 –
0.6 84.89 ± 0.47 85.23 ± 0.53 –
Dissolution medium 
temperature (°C)
36 85.31 ± 0.47 85.46 ± 0.53 –
37 84.25 ± 0.54 0.61 85.05 ± 0.42 0.55 –
38 84.56 ± 0.56 84.95 ± 0.48 –
a Mean ± SD, n = 3
b n = 9
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Linearity. – The results of the linearity study with their statistical analysis are given in 
Table III. For perindopril erbumine and perindopril arginine, the method was linear over 
the range from 12 to 60 μg mL–1 with the coeﬃ  cients of determination (R2) of 0.9988 and 
0.9995, respectively. The achieved LOD and LOQ values were 3.57 and 10.83 μg mL–1 for 
perindopril erbumine, and 3.23 and 11.93 μg mL–1 for perindopril arginine. For indapamide, 
the method was linear over the range from 3 to 15 μg mL–1 with the R2 of 0.9985. The achieved 
values of LOD and LOQ were 0.38 and 1.15 μg mL–1. Linearity was also assessed by defi ning 
the residuals of regression. The obtained residual plots confi rmed that regression residuals 
did not present a visible trend and were randomly scatt ered. The Shapiro Wilk test for nor-
mality did not reject the hypothesis that residuals were normally distributed. 
Precision. – The results of the precision study are given in Table IV. The repeatability 
(within-day precision) expressed as RSD was 0.1 % for perindopril erbumine. RSDs for 
indapamide were in the range from 0.1 to 0.6 %. The intermediate (day-to-day) precision 
was up to 0.4 % of perindopril erbumine, while for perindopril arginine it was 0.3 %. The 
respective values for indapamide were 0.5 %.
Accuracy. – Accuracy of the method was assessed by determining of perindopril and 
indapamide in fortifi ed samples at three levels of addition (Table V). For perindopril, re-
covery ranged from 96.9 to 99.0 % for the lowest and highest drug concentration, with  the 
mean RSD 0.7–2.2 %. For indapamide, recovery ranged from 101.1 to 100.9 % for the lowest 
and highest drug concentration, with the mean day-to-day RSD of 1.1 %. 
Assay in tablets
Precision of the method was also checked by the determining of perindopril and in-
dapamide in the tablets with respective RSD values of 0.2–0.4 and 0.4–0.8 %.
Dissolution study
The choice of optimal pH of dissolution medium was diﬃ  cult due to signifi cant dif-
ferences in chemical properties of perindopril and indapamide. Therefore, diﬀ erent phos-
phate buﬀ ers (pH 5.0, 5.5, 6.0 and 6.8) were examined as dissolution media. The eﬀ ect of 















erbumine 12–60 y = 65782x + 42240 0.3 16.9 0.9988 34212 < 0.001 3.57 10.83
Perindopril 
arginine 12–60 y = 67104x – 8185 0.3 15.9 0.9995 87116 < 0.001 3.23 11.93
Indapamide 3–15 y = 100160x + 44942 0.6 25.5 0.9985 26594 < 0.001 0.38 1.15
a n = 6
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the rotation speed of the paddle was also examined in the range of 50–100 rpm according 
to the European Pharmacopoeia (18). 
The best results for both perindopril and indapamide were obtained using the buﬀ er 
of pH 6.0 at 100 rpm though some individual results were below 80 %. According to USP 
(21), the use of surfactants is allowed to obtain higher dissolution values. Therefore, two 
diﬀ erent surfactants, cationic CPC and non-ionic Tween 80 in concentrations 0.02–0.5 %, 
were tried. Finally, phosphate buﬀ er of pH 6.0 containing 0.5 % Tween 80 was used for all 
dissolution tests. 
Robustness. – Robustness of the dissolution procedure was checked aft er deliberate 
alterations of % Tween 80 in the medium, pH of the buﬀ er in the medium and temperature. 
Respective dissolution tests along with quantitative assays were performed in triplicate 
and areas of the drugs were recorded for further estimation. It was shown that these small 
changes of the parameters did not lead to signifi cant changes of RSD recovery values. The 
RSD values were 0.6 % for perindopril and for indapamide (Table II), confi rming the ro-
bustness of the described dissolution procedure.
Comparison of dissolution profi les
Percent dissolution of perindopril and indapamide as a function of time are presented 
in Fig. 3. In pairwise procedures discussed below, three fi xed-dose formulations were 





Determineda RSD (%) Determinedb RSD (%)
Perindopril erbumine
24.0 23.25 ± 0.02 0.07 23.33 ± 0.09 0.37
40.0 38.65 ± 0.02 0.05 38.69 ± 0.05 0.13
56.0 54.40 ± 0.04 0.07 54.39 ± 0.01 0.02
Perindopril arginine
24.0 23.70 ± 0.08 0.33 23.66 ± 0.08 0.34
40.0 39.08 ± 0.17 0.45 39.08 ± 0.11 0.29
56.0 54.56 ± 0.06 0.12 54.48 ± 0.15 0.28
Indapamide
6.00 5.94 ± 0.01 0.10 5.93 ± 0.03 0.48
10.0 10.07 ± 0.02 0.21 10.09 ± 0.02 0.19
14.0 14.03 ± 0.09 0.63 14.06 ± 0.07 0.50
Mean ± SD (mg mL—1): a n = 3, b n = 9.
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compared in pairs: NF versus TK, NF versus CP and TK versus CP. In each pair, the fi rst 
formulation was considered as a test while the second as a reference product. 
First, similarity between dissolution profi les was assessed by the model independent 
methods such as the diﬀ erence factor f1, the similarity factor f2, Rescigno indices ξ1 and ξ2 
and the MD method (Table VI). 
The f1 factor measures the percent error between two curves over all time points. The f2 
factor is a logarithmic transformation of the sum-squared error of diﬀ erences between the 










Perindopril 32.0 97.47 ± 0.77 0.81
40.0 98.52 ± 0.52 0.53 98.34 ± 0.79 0.80
48.0 99.02 ± 0.51 0.51
Indapamide 8.00 101.75 ± 1.10 1.07
10.0 100.76 ± 0.61 0.61 101.1 ± 1.16 1.14
12.0 100.73 ± 0.57 0.57
Tertensif Kombi®
Perindopril 32.0 97.60 ± 2.33 2.40
40.0 97.29 ± 1.81 1.86 97.82 ± 0.67 0.69
48.0 98.58 ± 0.85 0.86
Indapamide 8.00 101.11 ± 1.10 1.07
10.0 101.02 ± 1.10 1.08 101.0 ± 1.07 1.05
12.0 100.91 ± 1.18 1.17
Co-Prenessa®
Perindopril 28.0 96.89 ± 0.04 0.62
36.0 97.64 ± 0.44 0.45 98.51 ± 0.22 2.22
44.0 98.79 ± 0.42 0.43
Indapamide 8.00 101.50 ± 0.96 0.46
10.0 100.50 ± 0.46 0.33 100.87 ± 1.11 1.10
12.0 100.67 ± 0.45 0.45
Mean ± SD (%): a n = 3, b n = 9.
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Fig. 3. Dissolution profi les of: a) indapamide and b) perindopril from Noliprel Forte®, Tertensif Kom-
bi® and Co-Prenessa® tablets (mean ± SD, n = 12 at each time interval).
test and the reference products over all time points. It is known from the literature that these 
factors are sensitive to the measurements beyond 85 % dissolution (11, 13, 14). In the present 
work, the values of f1 and f2 were calculated twice, once for the dissolution results up to 40 
min (the time at which the dissolution profi les nearly reached the fi nal plateau) and up to 60 
min (the time at which the dissolution process was completed). In the present work, all f1 
values are smaller than 15 and all f2 values are higher than 50, indicating that the examined 
products show similar dissolution profi les of perindopril and indapamide. Because of its 
simplicity, f2 method is recommended by EMA and FDA guidelines (15, 16). Nevertheless, it 
is not the optimal method mainly because of not taking into account the shape of the curve 
in a dissolution profi le. It is also sensitive to the number of time points used (11, 12, 21). 
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The Rescigno indices can be thought of as functions of the weighted average of the 
vertical distances between the test and reference mean profi les at each time point. In the 
present work, all Rescigno indices obtained for perindopril and indapamide are close to 
zero, indicating that the examined pairs of formulations show similar dissolution profi les. 
The Rescigno indices do not exert any major advantages over f1 or f2 factors, with the excep-
tion that interchanging the products in pair does not alter their values. As with f1 and f2 
factors, the Rescigno indices do not take into account the variability or correlation between 
respective dissolution time points (11, 15).
When the within-product variability has a coeﬃ  cient of variation greater than 15 %, 
a multivariate confi dence region procedure based on Mahalanobis distance (MD) is recom-
mended (11, 12, 16). In our study, all values of the upper limit of the confi dence interval 
(UPCI) are lower than the respective similarity limit (SL) indicating that all pairs of formu-
lations have similar dissolution profi les. This approach is not as simple to interpret as the 
f2 method. Also, the nature of the diﬀ erence between the mean dissolution profi les is not 
strictly defi ned. This means that profi les with large diﬀ erences at early time points and 
small diﬀ erences at later time points may yield the same value for the MD as mean dis-
solution profi les with small diﬀ erences at early time points and large diﬀ erences at later 
time points (11, 12).
On the other hand, some model independent methods take into account the variabili-
ty of dissolution curves, e.g. the methods based on AUC or MRT (12, 19). It was interesting 
to observe that these methods did not show similarity between three fi xed-dose formula-
tions, in contrast to other model-independent methods discussed above. 
Further, PCA was used to compare the dissolution profi les of perindopril and indap-
amide. This method is very useful, especially to visualize data variability (14, 21). In Fig. 4, 
plots of the weighed scores of the fi rst two PCs are presented for perindopril and indap-
Fig. 4. PC1 vs. PC2 scores plots for: a) indapamide and b) perindopril dissolved from Noliprel Forte® 
(1), Tertensif Kombi® (2) and Co-Prenessa® (3) tablets.
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amide. The examined formulations are described as 1 (NF), 2 (TK) and 3 (CP) and each 
product is represented by 12 points. In the data set obtained for perindopril, the PC1 is 
explanatory to 84.3 % while PC2 described 15.5 % of the total variance. For indapamide, 
the respective values of PC1 and PC2 are 89.2 and 10.6 %. The plots for perindopril and 
indapamide show that along PC1, respective dissolution points from 1 (NF) are located far 
away from two other formulations 2 (TK) and 3 (CP). It seems that the dissolution profi les 
of both drugs for these three products are nor similar. Additionally, for both perindopril 
and indapamide, the points from formulation 1 have evidently diﬀ erent scores along PC2 
than the points from formulations 2 and 3. It could be concluded that the dissolution pro-
fi le for 1 has a diﬀ erent shape than profi les for 2 and 3, for both drugs.
Table VII. The AIC values for the mathematical models (ref. 12) fi tt ed to the dissolution profi les of perindopril
Model Noliprel Forte® Tertensif Kombi® Co-Prenessa®
First-order                36.44415 34.77248 31.00554
First-order with Fmaxa      27.06262 33.34143 15.29032
First-order with Tlaga 35.29825 36.17412 28.62448
First-order with Tlaga and Fmaxa 28.91235 34.74951 17.27064
Gompertz 30.22312 35.85379 28.50177
Gompertz with Fmaxa 32.11875 37.12908 23.97992
Hixson-Crowell             43.60959 42.07886 42.00419
Hixson-Crowell with Tlaga 39.90886 40.28923 36.54190
Higuchi 47.47772 44.82222 42.94442
Higuchi with F0a 43.63776 44.55590 41.46322
Higuchi with Tlaga 44.92026 45.32972 42.55526
Korsmeyer-Peppas           42.12413 43.61894 40.12649
Logistic 2                 31.21082 36.22876 21.51761
Peppas-Sahlin          31.41325 35.52770 24.96117
Quadratic 45.37512 40.53122 42.01119
Quadratic with Tlaga 35.13124 35.11358 31.51846
Weibull 1                  32.69823 35.68629 25.64291
Weibull 2                  32.69823 36.85985 22.65522
Weibull 3                  28.66803 34.14105 17.21210
Zero-order                 59.12620 57.53103 57.19584
Zero-order with F0a 46.79082 47.86347 45.73334
Zero-order with Tlaga 46.79082 47.86347 45.73334
aF0  – initial fraction of the solution resulting from a burst release
Fmax – maximum fraction of the drug released at infi nite time
Tlag  – the lag time prior to drug release
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Table VIII. The AIC values for the mathematical models (ref. 12) fi tt ed to the dissolution profi les of indapamide
Model Noliprel Forte® Tertensif Kombi® Co-Prenessa®
First-order                36.73912 34.59528 30.62983
First-order with Fmaxa      24.20855 31.64352 13.92008
First-order with Tlaga 33.30772 34.83239 27.36750
First-order with Tlaga and Fmaxa 25.73668 33.61148 15.49636
Gompertz 26.81570 35.13727 28.44597
Gompertz with Fmaxa 28.38519 36.04252 22.43291
Hixson-Crowell             43.86255 42.37242 41.85304
Hixson-Crowell with Tlaga 38.42262 39.16109 35.94854
Higuchi 48.34935 45.35483 43.65520
Higuchi with F0a 42.28709 43.65211 41.36269
Higuchi with Tlaga 43.83206 44.65431 42.58625
Korsmeyer-Peppas           40.43366 42.46797 39.87341
Logistic 2                 27.58080 35.24502 19.80382
Peppas-Sahlin          29.87055 34.94374 25.14767
Quadratic 47.55915 42.87547 43.15908
Quadratic with Tlaga 35.26422 34.85393 32.09568
Weibull 1                  30.43932 34.10911 23.92524
Weibull 2                  28.85522 35.54786 20.55119
Weibull 3                  25.87895 33.43350 15.59772
Zero-order                 59.67752 58.06473 57.60860
Zero-order with F0a 45.58446 47.04676 45.59996
Zero-order with Tlaga 45.58446 47.04676 45.59996
aF0  – initial fraction of the drug in the solution resulting from a burst release
Fmax – maximum fraction of the drug released at infi nite time
Tlag – lag time prior to drug release
In the next step, the model-dependent approaches were applied for comparisons. 
First, a number of kinetic models were constructed and then estimated with the AIC values 
(Tables VII, VIII). The AIC is a measure of the goodness of fi t based on the maximum like-
lihood. When comparing several models for a given set of data, the model with the small-
est AIC is regarded as giving the best fi t (12). Considering the AIC for perindopril and in-
dapamide, the preferred model was the fi rst-order with Fmax. The second best were the 
fi rst-order with Tlag, Fmax and Weibull 3-model for both perindopril and indapamide. In the 
next step, the Fmax, Weibull and k1 models were used for additive pairwise comparisons. It 
is known from the literature that linearization of dissolution profi les using the above mod-
els could bett er characterize the diﬀ erences between these profi les. Especially, Weibull 
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Table IX. Comparison of the dissolution profi les of perindopril (P) and indapamide (I) from Noliprel Forte®, 
Tertensif Kombi® and Co-Prenessa® by the model-dependent methods
Drug/Formulations
Model-dependent method
k1 Fmax Weilbull model
t p t p p
NF × TK 164.996 < 2.2 10–16a –68.467 < 2.2 10–16a < 0.05a
P NF × CP 124.216 < 2.2 10–16a –25.416 1.35 10–14a < 0.05a
TK × CP –0.8974 0.3844 12.028 1.761 10–8a < 0.05a
NF × TK 306.98 < 2.2 10–16a –89.200 < 2.2 10–16a < 0.05a
I NF × CP 178.45 < 2.2 10–16a –37285 4.946 10–15a < 0.05a
TK × CP 20.693 2.24 10–10a –3.2847 0.006506a < 0.05a
a dissolution profi les are not similar 
k1  – the fi rst order release constant
Fmax  – maximum fraction of the drug released at infi nite time
parameters are frequently used to compare the dissolution profi les between the reference 
and test products (17, 19). When all these methods were used for NF, TK and CP formula-
tions, the dissolution profi les of both perindopril and indapamide were shown to be dis-
similar (Table IX). 
Overall, only some model-independent methods, i.e., f1 and f2, Rescigno and MD 
showed similarity of perindopril and indapamide profi les, when dissolved from three 
fi xed-dose formulations. Other model-independent procedures taking into account the 
variability of the curves (AUC and MRT methods) and all model-dependent methods as 
well as PCA did not show similarity for the same experimental data. Therefore, it was 
concluded that some recommended methods, especially the model-independent ones may 
be insuﬃ  cient. These methods allow the use of one arbitrarily chosen value for the diﬀ er-
ence allowed between the test and reference products (17). Our present results as well as 
some literature data (11, 14) suggest that diﬀ erences both in the level and the shape of dis-
solution curves are important when comparing profi les.
CONCLUSIONS
Quantitative data including dissolution profi les were obtained for three fi xed-dose 
formulations containing perindopril and indapamide using a new validated HPLC meth-
od. Since there is no suitable method in the literature, the procedure presented here can be 
used as a reliable quality control test for such combined formulations. In addition, diﬀ er-
ent mathematical approaches were used to compare dissolution profi les and many diﬀ er-
ences were found. It was concluded that discrimination between profi les was found when 
251
A. Gumieniczek et al.: Dissolution profi les of perindopril and indapamide in their fi xed-dose formulations by a new HPLC method 
and diﬀ erent mathematical approaches, Acta Pharm. 65 (2015) 235–252.
 
data variability within each formulation as well as the shape and size of the dissolution 
curves were taken into account. Because the three examined fi xed-dose formulations were 
obtained on the market, the most important question is what kind of diﬀ erence between 
the dissolution was considered to be of practical importance, e.g. having an impact on in 
vivo performance of a respective product.
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